These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 12532610)

  • 1. Monitoring antifactor Xa activity of the low-molecular-weight heparins in the clinical setting: who, why, how, and when?
    Kalus JS; White CM
    Conn Med; 2002 Dec; 66(12):749-52. PubMed ID: 12532610
    [No Abstract]   [Full Text] [Related]  

  • 2. Limitations of the chronometric assays to determine plasma antifactor Xa activity during low molecular weight heparin therapy.
    Boneu B; Faruel-Bille V; Pierrejean D; Gabaig AM
    Nouv Rev Fr Hematol (1978); 1991; 33(4):287-91. PubMed ID: 1664095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new chronometric assay to determine plasma antifactor Xa activity which is insensitive to the antithrombin activity of low molecular weight heparins.
    Dignac M; Gabaig AM; Cambus JP; Boneu B
    Nouv Rev Fr Hematol (1978); 1994; 35(6):545-9. PubMed ID: 8152901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction.
    Brophy DF; Martin EJ; Best AM; Gehr TW; Carr ME
    J Thromb Haemost; 2004 Aug; 2(8):1299-304. PubMed ID: 15304034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-factor Xa levels: when should they be used?
    Clem JR
    S D Med; 2006 Jun; 59(6):261-2. PubMed ID: 16821477
    [No Abstract]   [Full Text] [Related]  

  • 6. The contribution of anti-Xa and anti-IIa activities to the profibrinolytic activity of low-molecular-weight heparins.
    Ammollo CT; Semeraro F; Semeraro N; Colucci M
    Thromb Haemost; 2009 Apr; 101(4):782-5. PubMed ID: 19350129
    [No Abstract]   [Full Text] [Related]  

  • 7. [Anticoagulant activity of low-molecular-weight heparins obtained using a hydrolase complex].
    Drozd NN; Tolstenkov AS; Bannikova GE; Miftakhova NT; Lapikova ES; Makarov VA; Varlamov VP
    Eksp Klin Farmakol; 2007; 70(6):19-24. PubMed ID: 18318190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is the monitoring of anti-Xa activity necessary in pregnant women undergoing thromboprophylaxis?
    O'Connell MP; O'Leary M; MacKeogh L; Murphy K; Keane DP
    Eur J Obstet Gynecol Reprod Biol; 2004 May; 114(1):12-4. PubMed ID: 15099863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring Unfractionated Heparin (UFH) therapy: which Anti-Factor Xa assay is appropriate?
    Ignjatovic V; Summerhayes R; Gan A; Than J; Chan A; Cochrane A; Bennett M; Horton S; Shann F; Lane G; Ross-Smith M; Monagle P
    Thromb Res; 2007; 120(3):347-51. PubMed ID: 17118432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of calcium ions on the interactions between antithrombin and factor Xa mediated by variously sulfated, semisynthetic low-molecular-weight heparins.
    Sissi C; Lucatello L; Naggi A; Torri G; Palumbo M
    Semin Thromb Hemost; 2002 Aug; 28(4):355-60. PubMed ID: 12244482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin and low molecular weight heparin: is anti-factor Xa activity important?
    Lane DA; Ryan K
    J Lab Clin Med; 1989 Oct; 114(4):331-3. PubMed ID: 2551984
    [No Abstract]   [Full Text] [Related]  

  • 12. Heparin and low-molecular-weight heparin.
    Gray E; Mulloy B; Barrowcliffe TW
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between ex vivo anti-factor Xa levels and efficacy/safety of low molecular weight heparin.
    Turpie AG
    Br J Clin Pract Suppl; 1989 Jan; 65():18-23; discussion 23-5. PubMed ID: 2554949
    [No Abstract]   [Full Text] [Related]  

  • 14. Specific anti-Xa activity of LMWH (Kabi 2165, CY 216, PK 10169) against the first international standard of LMWH: a collaborative study.
    Dautzenberg MD; Bara L; Cornu P; Samama M
    Thromb Haemost; 1990 Nov; 64(3):490-1. PubMed ID: 1965752
    [No Abstract]   [Full Text] [Related]  

  • 15. [Apropos of the monitoring of treatment with low molecular weight heparins].
    Toulemonde F; Bayrou B
    Ann Biol Clin (Paris); 1989; 47(9):561-2. PubMed ID: 2558600
    [No Abstract]   [Full Text] [Related]  

  • 16. In vitro protamine neutralization profiles of heparins differing in source and molecular weight.
    Racanelli A; Hoppensteadt DA; Fareed J
    Semin Thromb Hemost; 1989 Oct; 15(4):386-9. PubMed ID: 2554498
    [No Abstract]   [Full Text] [Related]  

  • 17. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are all low molecular weight heparins equivalent in the management of venous thromboembolism?
    Fareed J; Jeske W; Fareed D; Clark M; Wahi R; Adiguzel C; Hoppensteadt D
    Clin Appl Thromb Hemost; 2008 Oct; 14(4):385-92. PubMed ID: 18815137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemistry and pharmacology of low molecular weight heparin.
    Rosenberg RD
    Semin Hematol; 1997 Oct; 34(4 Suppl 4):2-8. PubMed ID: 9399404
    [No Abstract]   [Full Text] [Related]  

  • 20. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes.
    Harenberg J
    J Thromb Haemost; 2004 Apr; 2(4):547-50. PubMed ID: 15102006
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.